CN113527203B - 乐伐替尼甲磺酸盐的晶型及其制备方法和用途 - Google Patents

乐伐替尼甲磺酸盐的晶型及其制备方法和用途 Download PDF

Info

Publication number
CN113527203B
CN113527203B CN202110477564.4A CN202110477564A CN113527203B CN 113527203 B CN113527203 B CN 113527203B CN 202110477564 A CN202110477564 A CN 202110477564A CN 113527203 B CN113527203 B CN 113527203B
Authority
CN
China
Prior art keywords
formula
compound
lenvatinib mesylate
degrees
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110477564.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113527203A (zh
Inventor
陈敏华
张炎锋
刁小娟
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing F&s Pharmatech Co ltd
Original Assignee
Nanjing Obsidian And Medical Science And Technology Co ltd
Nanjing F&s Pharmatech Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Obsidian And Medical Science And Technology Co ltd, Nanjing F&s Pharmatech Co ltd filed Critical Nanjing Obsidian And Medical Science And Technology Co ltd
Priority to CN202110477564.4A priority Critical patent/CN113527203B/zh
Publication of CN113527203A publication Critical patent/CN113527203A/zh
Application granted granted Critical
Publication of CN113527203B publication Critical patent/CN113527203B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C255/03—Mononitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
CN202110477564.4A 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途 Active CN113527203B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110477564.4A CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201510263300 2015-05-21
PCT/CN2016/085360 WO2016184436A1 (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法
CN202110477564.4A CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CN201680036277.7A CN107848979A (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680036277.7A Division CN107848979A (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN113527203A CN113527203A (zh) 2021-10-22
CN113527203B true CN113527203B (zh) 2023-07-25

Family

ID=57319484

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110477564.4A Active CN113527203B (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CN201680036277.7A Pending CN107848979A (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680036277.7A Pending CN107848979A (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Country Status (7)

Country Link
US (1) US10246418B2 (https=)
EP (1) EP3287444A4 (https=)
JP (1) JP2018520205A (https=)
CN (2) CN113527203B (https=)
IL (1) IL255738A (https=)
MX (1) MX2017014799A (https=)
WO (1) WO2016184436A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
JP6524220B2 (ja) 2014-09-30 2019-06-05 エルジー・ケム・リミテッド ブロック共重合体
US10562855B2 (en) * 2016-06-08 2020-02-18 Crystal Pharmatech Co., Ltd. Crystalline form of lenvantinib mesylate and process of preparation thereof
RU2019123542A (ru) * 2016-12-29 2021-02-01 Др. Редди'З Лабораториз Лимитед Формы твердой фазы мезилата ленватиниба
CN110494423B (zh) * 2017-04-25 2022-04-26 苏州科睿思制药有限公司 乐伐替尼甲磺酸盐的新晶型及其制备方法
WO2019111283A1 (en) * 2017-12-09 2019-06-13 Msn Laboratories Private Limited, R&D Center Novel polymorphs of 4-[3-chloro-4-(n'-cyclopropyl ureido)phenoxy]-7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
CN112204011A (zh) * 2018-06-01 2021-01-08 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼新晶型及其制备方法
CN110818634B (zh) * 2018-08-13 2021-11-30 上海新礼泰药业有限公司 甲磺酸乐伐替尼的精制方法
EP3620453A1 (en) 2018-09-07 2020-03-11 Indena S.p.A. New crystal form of lenvatinib
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN111689897B (zh) * 2019-03-13 2024-02-06 齐鲁制药有限公司 一种高纯度甲磺酸乐伐替尼晶型c的制备方法
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法
CN110229103A (zh) * 2019-06-27 2019-09-13 尚科生物医药（上海）有限公司 一种乐伐替尼甲磺酸盐晶型b的制备方法
CN112174886A (zh) * 2019-07-02 2021-01-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼晶型x的制备方法
WO2021007189A1 (en) * 2019-07-08 2021-01-14 Rezolute, Inc. Crystalline forms of plasma kallikrein inhibitors
CN110563644A (zh) * 2019-10-30 2019-12-13 北京赛思源生物医药技术有限公司 一种仑伐替尼甲磺酸盐的新晶型
US11059787B2 (en) 2019-11-12 2021-07-13 Shenzhen Bolan Pharmaceutical Co., Ltd Crystalline form of lenvatinib mesylate and methods thereof
CN113135853A (zh) * 2020-01-19 2021-07-20 重庆医药工业研究院有限责任公司 一种氟伐替尼或甲磺酸盐的晶型及其制备方法
KR102581450B1 (ko) * 2020-04-24 2023-09-21 청두 이스턴 바이오파마슈티컬 컴퍼니 리미티드 렌바티닙 메실레이트의 결정형 xi 및 이의 제조방법
CN112939859B (zh) * 2021-02-03 2022-03-11 南京方生和医药科技有限公司 甲磺酸仑伐替尼m晶型的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1890220A (zh) * 2003-12-25 2007-01-03 卫材株式会社 4－(3－氯－4－(环丙基氨基羰基)氨基苯氧基)－7－甲氧基－6－喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法
CN101001629A (zh) * 2004-09-17 2007-07-18 卫材R&D管理有限公司 药物组合物
CN102470133A (zh) * 2009-08-19 2012-05-23 卫材R&D管理有限公司 含有喹啉衍生物的药物组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
JP4733700B2 (ja) * 2005-06-23 2011-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 ４−（３−クロロ−４−（シクロプロピルアミノカルボニル）アミノフェノキシ）−７−メトキシ−６−キノリンカルボキサミドの塩のアモルファスおよびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1890220A (zh) * 2003-12-25 2007-01-03 卫材株式会社 4－(3－氯－4－(环丙基氨基羰基)氨基苯氧基)－7－甲氧基－6－喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法
CN101001629A (zh) * 2004-09-17 2007-07-18 卫材R&D管理有限公司 药物组合物
CN102470133A (zh) * 2009-08-19 2012-05-23 卫材R&D管理有限公司 含有喹啉衍生物的药物组合物

Also Published As

Publication number Publication date
JP2018520205A (ja) 2018-07-26
US20180155291A1 (en) 2018-06-07
EP3287444A4 (en) 2018-09-12
EP3287444A1 (en) 2018-02-28
CN113527203A (zh) 2021-10-22
WO2016184436A1 (zh) 2016-11-24
IL255738A (en) 2018-01-31
US10246418B2 (en) 2019-04-02
MX2017014799A (es) 2023-02-23
CN107848979A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
CN113527203B (zh) 乐伐替尼甲磺酸盐的晶型及其制备方法和用途
CN107428727B (zh) 来那替尼马来酸盐的新晶型及其制备方法
CN105753789B (zh) 奥拉帕尼与尿素的共晶及其制备方法
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
KR102886764B1 (ko) Cdk9 억제제의 결정다형 및 이의 제조방법과 용도
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
CN105801476A (zh) 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用
CN107428779A (zh) 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
US9453011B2 (en) Crystal form of dabrafenib mesylate and preparation method thereof
CN110903239A (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
CN104628677A (zh) 一种沃替西汀有机酸盐晶型及其制备方法
WO2016101867A1 (zh) 萘普替尼对甲苯磺酸盐的α晶型及制备方法和含有其的药物组合物
CN103058922B (zh) 用于抗肿瘤药物的芳香脲的晶型及其制备方法
CN104961681B (zh) 卡博替尼的粘酸盐及其晶型
CN104961680B (zh) N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN112566904A (zh) 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法
CN107118153A (zh) 一种瑞戈非尼一水合物晶型及其制备方法
US10562855B2 (en) Crystalline form of lenvantinib mesylate and process of preparation thereof
CN106478603B (zh) 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途
CN111732586B (zh) 含炔基化合物盐的晶型、制备方法及应用
CN103664771A (zh) 索拉非尼的晶型a及其制备方法
CN102977083A (zh) 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法
CN107954947A (zh) 沃替西汀氢溴酸盐晶型c及其制备方法
WO2016101868A1 (zh) 萘普替尼对甲苯磺酸盐的β晶型及制备方法和含有其的药物组合物
CN104558034A (zh) 磷酸特地唑胺二钠盐的新晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250926

Address after: 211800 Jiangsu Province Nanjing City Pukou District Pukou Economic Development Zone Baihe Road 111 Zifeng Yanchuang Center Phase I Building 2

Patentee after: NANJING F&S PHARMATECH CO.,LTD.

Country or region after: China

Address before: No.12-1800, Building 29, yulinkou street, puqiao District, Nanjing City, Jiangsu Province

Patentee before: NANJING F&S PHARMATECH CO.,LTD.

Country or region before: China

Patentee before: Nanjing obsidian and medical science and Technology Co.,Ltd.

TR01 Transfer of patent right